Medical School · Year 2 · Immunology · includes a quiz and discussion video

Lecture 7: Autoimmunity

Unit 2.7: Immunology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the mechanisms of central and peripheral tolerance
2. Explain the pathogenesis of autoimmune diseases
3. Describe organ-specific autoimmune disorders
4. Explain systemic autoimmune diseases
5. Describe autoantibodies and their clinical utility
6. Explain the principles of immunotherapy for autoimmune diseases

Lecture Outline

I. Immunological Tolerance

Immunological tolerance refers to the state of unresponsiveness to specific antigens, particularly self-antigens, and represents the fundamental mechanism by which the adaptive immune system avoids attacking the body's own tissues. The immune system must accomplish two seemingly contradictory tasks: generating sufficient diversity to recognize virtually any foreign antigen while simultaneously preventing responses against the enormous array of self-antigens. Failure of tolerance mechanisms results in autoimmunity, wherein the immune system mounts pathological responses against self-tissues. Understanding tolerance is therefore essential for understanding both normal immunity and the pathogenesis of autoimmune diseases.

Central tolerance operates during lymphocyte development in the primary lymphoid organs (thymus for T cells, bone marrow for B cells) and eliminates or modifies self-reactive lymphocytes before they mature and enter the peripheral circulation. In the thymus, T cells whose receptors bind self-peptide-MHC complexes with high affinity undergo negative selection through apoptosis, eliminating the most overtly self-reactive clones. The autoimmune regulator (AIRE) transcription factor plays a critical role by driving expression of tissue-specific antigens in medullary thymic epithelial cells, allowing deletion of T cells reactive against proteins normally expressed only in peripheral tissues such as insulin, thyroglobulin, and myelin proteins. AIRE deficiency causes autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), demonstrating the essential role of central tolerance in preventing organ-specific autoimmunity.

Peripheral tolerance mechanisms act on mature lymphocytes that have escaped central tolerance, providing multiple layers of protection against autoimmunity. Anergy refers to a state of functional unresponsiveness that develops when T cells recognize antigen without adequate costimulation, as typically occurs when self-antigens are presented by non-professional APCs lacking CD80/86. Anergic T cells remain alive but cannot respond productively to subsequent antigen encounter. Activation-induced cell death (AICD) eliminates T cells that are repeatedly stimulated, preventing accumulation of potentially harmful activated cells. Perhaps most importantly, regulatory T cells (Tregs) actively suppress autoreactive T cells that escape other tolerance mechanisms, providing dominant tolerance that can control immune responses against self-antigens.

Immunologically privileged sites are anatomical locations where immune responses are limited or absent, providing additional protection for sensitive tissues. The eye, brain, testis, and placenta represent classically privileged sites, protected by physical barriers (blood-brain barrier, blood-ocular barrier), local immunosuppressive factors (TGF-beta, FasL expression), and limited lymphatic drainage preventing antigen delivery to secondary lymphoid organs. However, privilege is not absolute, and inflammation or trauma can breach these barriers and expose previously sequestered antigens to the immune system. Sympathetic ophthalmia, in which trauma to one eye induces autoimmune uveitis affecting both eyes, exemplifies how breach of immunological privilege can trigger autoimmunity against sequestered antigens.

<image> Panel A: Central tolerance mechanisms diagram showing thymic positive and negative selection with AIRE-expressing medullary thymic epithelial cells presenting tissue-specific antigens (insulin, thyroglobulin, myelin) for deletion of self-reactive thymocytes, and bone marrow B cell tolerance through receptor editing, deletion, and anergy Panel B: Peripheral tolerance mechanisms showing anergy induction when T cell receives TCR signal without costimulation from non-professional APC, activation-induced cell death following repeated stimulation with Fas-FasL interaction, and Treg-mediated suppression through CTLA-4, IL-10, TGF-beta, and IL-2 consumption Panel C: Regulatory T cell differentiation and function showing thymic Treg development (intermediate affinity self-recognition leads to Foxp3 expression rather than deletion), peripheral iTreg induction in tolerogenic conditions, and the multiple suppressive mechanisms employed by Tregs Panel D: Immunologically privileged sites illustration showing the eye (blood-ocular barrier, TGF-beta, FasL), brain (blood-brain barrier, limited MHC expression), testis (blood-testis barrier, immunosuppressive factors), and placenta (HLA-G, Tregs), with explanation of how privilege is maintained and how it can be breached </image>

II. Breakdown of Tolerance

The development of autoimmune disease requires failure of both central and peripheral tolerance mechanisms, and is typically multifactorial, involving genetic susceptibility combined with environmental triggers. No single defect is usually sufficient to cause autoimmunity; rather, multiple "hits" accumulate to tip the balance from tolerance to autoimmunity. This model explains why autoimmune diseases often have complex inheritance patterns, incomplete penetrance even in monozygotic twins, and variable age of onset despite genetic predisposition being present from birth.

Genetic factors contribute substantially to autoimmune disease risk, with HLA genes providing the strongest genetic associations. Different HLA alleles confer risk for different autoimmune diseases, reflecting the central role of antigen presentation in determining which self-peptides are presented and which T cell specificities are selected in the thymus. Beyond HLA, polymorphisms in genes affecting immune regulation also contribute to risk. AIRE mutations cause severe multi-organ autoimmunity due to impaired central tolerance. FOXP3 mutations cause IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) due to Treg deficiency. CTLA-4 polymorphisms are associated with multiple autoimmune diseases including type 1 diabetes and thyroid disease. PTPN22, encoding a phosphatase that regulates T cell and B cell receptor signaling, is associated with rheumatoid arthritis, type 1 diabetes, and systemic lupus erythematosus.

Environmental factors serve as triggers that initiate autoimmune responses in genetically susceptible individuals. Infections can trigger autoimmunity through several mechanisms. Molecular mimicry occurs when microbial antigens share structural similarity with self-antigens, so that immune responses against the pathogen cross-react with host tissues; the classic example is rheumatic fever, where antibodies against streptococcal M protein cross-react with cardiac myosin. Bystander activation occurs when infection-induced inflammation and tissue damage release self-antigens and provide the inflammatory context that can activate autoreactive lymphocytes. Epitope spreading describes how an initial autoimmune response against one epitope can broaden to include additional epitopes on the same protein or other proteins, perpetuating and diversifying the autoimmune response.

Additional environmental factors implicated in autoimmunity include hormones (explaining female predominance of many autoimmune diseases), the microbiome (gut dysbiosis associated with inflammatory bowel disease and other conditions), drugs (drug-induced lupus, immune checkpoint inhibitor-induced autoimmunity), and ultraviolet radiation (exacerbating lupus and triggering dermatomyositis). The hygiene hypothesis proposes that reduced infectious exposure in modern developed societies contributes to increased autoimmunity by skewing immune development toward Th2 responses and reducing Treg function. While specific causal relationships are difficult to prove, the rising incidence of autoimmune diseases in developed countries over recent decades supports environmental contributions beyond genetics alone.

<image> Panel A: Genetic susceptibility diagram showing HLA associations (B27 with AS, DR4 with RA, DR3/DR4 with T1DM), non-HLA immune regulatory genes (AIRE, FOXP3, CTLA-4, PTPN22), and how polygenic risk accumulates, illustrated with risk score distribution showing overlap between affected and unaffected populations Panel B: Molecular mimicry mechanism showing microbial antigen with epitope resembling self-antigen, immune response initially targeting microbe, cross-reactive antibodies or T cells subsequently attacking host tissue with shared epitope, with specific examples (streptococcal M protein and cardiac myosin in rheumatic fever) Panel C: Bystander activation and epitope spreading showing infection causing tissue damage and inflammation, release of self-antigens in inflammatory context, activation of autoreactive T cells that escaped tolerance, and progressive expansion of response to additional epitopes over time Panel D: Environmental triggers overview showing infections (EBV associated with SLE and MS), hormones (estrogen promoting B cell survival and autoantibody production, explaining female predominance), microbiome (dysbiosis affecting intestinal barrier and immune regulation), and drugs (checkpoint inhibitors, procainamide, hydralazine) </image>

III. Mechanisms of Autoimmune Damage

Autoimmune diseases cause tissue damage through the same effector mechanisms used in protective immunity, categorized using the Gell and Coombs classification of hypersensitivity reactions. Understanding the predominant mechanism of damage in each disease is clinically important because it guides therapeutic approaches. Most autoimmune diseases involve Type II (antibody-mediated) or Type IV (T cell-mediated) hypersensitivity, with many diseases involving contributions from both, while Type III (immune complex) mechanisms feature prominently in systemic lupus erythematosus.

Type II hypersensitivity mechanisms involve antibodies directed against cell surface or tissue antigens, causing damage through complement activation, antibody-dependent cellular cytotoxicity (ADCC), or direct interference with receptor function. Complement activation by bound antibodies generates the membrane attack complex that lyses cells (as in autoimmune hemolytic anemia) and generates anaphylatoxins (C3a, C5a) that recruit inflammatory cells. ADCC occurs when Fc receptors on NK cells and macrophages bind antibody-coated cells, triggering cytotoxicity and phagocytosis. Notably, some antibodies cause disease by directly affecting receptor function without requiring complement or inflammatory cells: stimulating antibodies in Graves' disease activate the TSH receptor causing hyperthyroidism, while blocking antibodies in myasthenia gravis prevent acetylcholine receptor activation causing weakness.

Type III hypersensitivity involves formation and deposition of immune complexes (antigen-antibody aggregates), which activate complement and recruit inflammatory cells, causing tissue damage particularly in blood vessel walls, glomeruli, and joints. The size and composition of immune complexes determine where they deposit: small complexes with antigen excess may circulate and deposit at sites of filtration and turbulent blood flow. SLE nephritis exemplifies Type III mechanisms, with DNA-anti-DNA complexes depositing in glomeruli and activating complement. Immune complex disease can also result from exogenous antigens, as in serum sickness from foreign proteins and post-streptococcal glomerulonephritis from streptococcal antigens.

Type IV hypersensitivity mechanisms involve T cell-mediated tissue damage, either through direct cytotoxicity by CD8+ T cells or through CD4+ T cell recruitment and activation of macrophages. In type 1 diabetes, CD8+ cytotoxic T cells directly kill pancreatic beta cells after recognizing beta cell-derived peptides presented on MHC class I. In multiple sclerosis, Th1 and Th17 CD4+ T cells infiltrate the CNS, activate microglia and recruit macrophages that damage myelin. In rheumatoid arthritis, CD4+ T cells in the synovium produce inflammatory cytokines that activate synovial fibroblasts and macrophages, which in turn produce metalloproteinases and other factors that destroy cartilage and bone. Most autoimmune diseases involve mixed mechanisms, with both antibody and T cell contributions, and the relative importance may vary among patients and over the disease course.

<image> Panel A: Type II hypersensitivity mechanisms in autoimmunity showing antibody binding to cell surface antigen, three outcomes: complement activation (MAC-mediated lysis, opsonization), ADCC (NK cell Fc receptor binding leading to target cell killing), and direct receptor effects (stimulation in Graves', blockade in myasthenia gravis) Panel B: Type III hypersensitivity showing immune complex formation in slight antigen excess (pathogenic size), deposition in glomerular basement membrane and vessel walls, complement activation generating C5a chemotaxis and C3b opsonization, neutrophil recruitment and tissue damage, with lupus nephritis as example Panel C: Type IV hypersensitivity showing CD8+ CTL directly killing target cell (as in T1DM beta cell destruction), and CD4+ Th1/Th17 cells activating macrophages through IFN-gamma (as in MS microglia activation and RA synovial macrophage activation), with resulting tissue damage patterns Panel D: Mixed mechanisms summary showing how most autoimmune diseases involve multiple mechanisms, with rheumatoid arthritis as example showing T cell cytokine production, autoantibodies (RF, anti-CCP) forming immune complexes, and the resulting pannus formation with cartilage and bone destruction </image>

IV. Organ-Specific Autoimmune Diseases - Endocrine

Organ-specific autoimmune diseases target single organs or tissues, typically with autoantibodies specific for tissue-restricted antigens. The endocrine organs are particularly susceptible to autoimmune attack, perhaps due to their high secretory activity and antigen exposure. Endocrine autoimmune diseases often cluster in individuals and families, sharing genetic susceptibility factors, and a patient with one organ-specific autoimmune disease is at increased risk for developing others.

Type 1 diabetes mellitus (T1DM) results from T cell-mediated destruction of insulin-producing pancreatic beta cells, leading to absolute insulin deficiency requiring lifelong insulin replacement. The process occurs over months to years, during which progressively more beta cells are destroyed, until insulin production becomes insufficient for glucose homeostasis. Histologically, insulitis refers to lymphocytic infiltration of islets, with CD8+ cytotoxic T cells being the primary effectors of beta cell killing. CD4+ T cells provide help and shape the response. Multiple autoantibodies are present before and at diagnosis, serving as biomarkers of autoimmunity: anti-glutamic acid decarboxylase (GAD65), anti-insulin, anti-islet antigen 2 (IA-2), and anti-zinc transporter 8 (ZnT8). These autoantibodies indicate ongoing autoimmunity and predict progression to clinical diabetes, but are not thought to be directly pathogenic. HLA-DR3 and DR4, particularly the linked DQ2 and DQ8 alleles, confer the strongest genetic risk.

Autoimmune thyroid diseases include both hypothyroidism (Hashimoto's thyroiditis) and hyperthyroidism (Graves' disease), representing different outcomes of thyroid-directed autoimmunity. Hashimoto's thyroiditis involves progressive destruction of thyroid follicular cells by cytotoxic T cells and antibody-mediated mechanisms, eventually leading to hypothyroidism requiring thyroid hormone replacement. Anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies are characteristic, and histology shows lymphocytic infiltration with germinal center formation. Graves' disease is uniquely caused by stimulating autoantibodies (thyroid-stimulating immunoglobulin, TSI) that bind and activate the TSH receptor, causing thyroid hormone overproduction independent of normal feedback regulation. Clinical features include hyperthyroidism, diffuse goiter, and in some patients, ophthalmopathy (exophthalmos, periorbital edema) and dermopathy (pretibial myxedema) due to TSH receptor autoimmunity affecting orbital fibroblasts and skin.

Autoimmune Addison's disease (primary adrenal insufficiency) results from destruction of the adrenal cortex by autoimmune mechanisms, leading to deficiency of cortisol, aldosterone, and adrenal androgens. Autoantibodies against 21-hydroxylase, a key enzyme in steroid hormone synthesis, are present in approximately 90% of patients and serve as diagnostic markers. The disease may occur in isolation or as part of autoimmune polyendocrine syndromes (APS). APS type 1 (APECED) results from AIRE mutations and includes adrenal insufficiency, hypoparathyroidism, and mucocutaneous candidiasis. APS type 2 includes adrenal insufficiency with autoimmune thyroid disease and/or type 1 diabetes, and has a polygenic basis with HLA-DR3 and DR4 associations. The clustering of organ-specific autoimmune diseases reflects shared genetic susceptibility factors affecting general mechanisms of immune tolerance.

<image> Panel A: Type 1 diabetes pathogenesis showing genetic susceptibility (HLA-DR3/DR4, DQ2/DQ8), environmental trigger, insulitis development with CD8+ CTL and CD4+ T cell infiltration of islets, progressive beta cell destruction over time (illustrated with timeline from presymptomatic to clinical onset), and autoantibody markers (anti-GAD, anti-insulin, anti-IA2, anti-ZnT8) Panel B: Autoimmune thyroid diseases comparison showing Hashimoto's thyroiditis (lymphocytic infiltration, anti-TPO/anti-Tg antibodies, progressive destruction leading to hypothyroidism) versus Graves' disease (TSI stimulating TSH receptor, autonomous hormone production leading to hyperthyroidism), with clinical features of each Panel C: Graves' ophthalmopathy mechanism showing TSH receptor expression on orbital fibroblasts, autoantibody and T cell targeting of these cells, fibroblast activation and glycosaminoglycan production, orbital muscle inflammation and fat expansion, resulting in proptosis and periorbital changes Panel D: Autoimmune polyendocrine syndromes showing APS-1 (APECED: AIRE mutation, hypoparathyroidism, adrenal insufficiency, CMC, early onset) versus APS-2 (polygenic, adrenal insufficiency with thyroid disease and/or T1DM, HLA-associated, adult onset), illustrating the clustering of organ-specific autoimmunity </image>

V. Organ-Specific Autoimmune Diseases - Other

Beyond the endocrine system, organ-specific autoimmunity can affect virtually any tissue, including the nervous system, blood cells, gastrointestinal tract, and skin. These conditions share the common feature of autoantibodies or T cells targeting tissue-specific antigens, but differ dramatically in their clinical manifestations depending on the physiological function of the affected tissue and the mechanism of immune-mediated damage.

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system characterized by discrete lesions (plaques) disseminated in time and space throughout the white matter. The pathological hallmark is destruction of myelin sheaths surrounding axons, with relative preservation of axons early in disease but progressive axonal loss contributing to irreversible disability. CD4+ Th1 and Th17 cells reactive against myelin antigens (myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein) are believed to initiate lesions, crossing the blood-brain barrier and activating resident microglia and infiltrating macrophages that effect myelin destruction. B cells and antibodies also contribute, evidenced by the presence of oligoclonal bands in cerebrospinal fluid and the efficacy of B cell-depleting therapies. MS typically follows a relapsing-remitting course initially, with neurological deficits developing over days and partially or completely resolving, but many patients eventually develop secondary progressive disease with gradual accumulation of disability.

Myasthenia gravis (MG) results from autoantibodies targeting the neuromuscular junction, most commonly antibodies against the acetylcholine receptor (AChR) on the postsynaptic muscle membrane. These antibodies cause disease through multiple mechanisms: accelerated AChR internalization and degradation, complement-mediated damage to the postsynaptic membrane, and direct blockade of acetylcholine binding. The clinical hallmark is fatigable weakness, worsening with repeated muscle use and improving with rest, reflecting progressive failure of neuromuscular transmission as acetylcholine vesicles are depleted faster than neuromuscular transmission can be maintained with reduced AChR density. Ocular muscles are most commonly affected (ptosis, diplopia), but weakness can involve bulbar muscles (dysarthria, dysphagia), limb muscles, and respiratory muscles. The thymus is abnormal in most patients, with thymic hyperplasia in approximately 65% and thymoma in approximately 15%, suggesting thymic involvement in disease pathogenesis. A subset of patients have antibodies against muscle-specific kinase (MuSK) rather than AChR, with distinct clinical features and treatment responses.

Autoimmune hemolytic anemia (AIHA) exemplifies antibody-mediated cytopenia, where autoantibodies targeting red blood cell antigens cause accelerated RBC destruction. Warm AIHA, the most common form, involves IgG antibodies that bind RBCs optimally at body temperature, causing primarily extravascular hemolysis as antibody-coated RBCs are removed by splenic macrophages bearing Fc receptors. Cold AIHA involves IgM antibodies that bind RBCs at lower temperatures (periphery, extremities), fix complement, and can cause intravascular hemolysis through complement-mediated lysis or extravascular hemolysis through complement receptor-mediated phagocytosis. Diagnosis requires demonstration of a positive direct antiglobulin test (Coombs test), which detects antibody or complement bound to patient RBCs. Pernicious anemia, though not a hemolytic anemia, is another hematologically relevant autoimmune condition, caused by autoantibodies against gastric parietal cells and intrinsic factor leading to vitamin B12 malabsorption and megaloblastic anemia.

<image> Panel A: Multiple sclerosis pathogenesis showing autoreactive T cell activation in periphery, migration across blood-brain barrier, reactivation by local APCs presenting myelin antigens, microglia and macrophage activation, myelin destruction with relative axonal preservation early and axonal loss later, oligoclonal B cell response, and resulting demyelinated plaque Panel B: Myasthenia gravis at neuromuscular junction showing normal junction with AChR clustered at postsynaptic membrane, MG junction with anti-AChR antibodies causing accelerated receptor internalization, complement damage to membrane folds, and reduced AChR density, resulting in failed neuromuscular transmission with repeated stimulation Panel C: Autoimmune hemolytic anemia types showing warm AIHA (IgG antibodies, extravascular hemolysis via splenic macrophage Fc receptors, spherocytes on smear) versus cold AIHA (IgM antibodies, complement fixation, intravascular hemolysis and/or extravascular via complement receptors), with direct Coombs test interpretation Panel D: Pernicious anemia mechanism showing autoantibodies against parietal cells (reducing acid and intrinsic factor production) and against intrinsic factor itself (blocking B12 binding or B12-IF complex absorption in terminal ileum), resulting in B12 deficiency with megaloblastic anemia and neurological manifestations </image>

VI. Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disease, characterized by autoantibodies against nuclear antigens, immune complex deposition causing inflammation in multiple organs, and diverse clinical manifestations that can affect virtually any organ system. SLE predominantly affects women of childbearing age, with a female-to-male ratio of approximately 9:1, and is more common and often more severe in individuals of African, Asian, and Hispanic ancestry. The clinical course is typically characterized by flares and remissions, with the goal of treatment being to control disease activity, prevent organ damage, and minimize treatment toxicity.

The pathogenesis of SLE centers on defective clearance of apoptotic cells and nuclear debris, leading to prolonged exposure of nuclear antigens to the immune system. Normally, apoptotic cells are rapidly phagocytosed before membrane integrity is lost, and nucleosomes and other intracellular contents are not exposed to the immune system. In SLE, genetic variants affecting apoptotic cell clearance (complement deficiencies, phagocyte function abnormalities) allow nuclear antigens to be released and persist extracellularly, where they can be recognized by the immune system. DNA-containing immune complexes stimulate plasmacytoid dendritic cells through TLR9 to produce type I interferons, creating a characteristic interferon signature that amplifies B cell and T cell activation. The production of antinuclear antibodies (ANA) creates immune complexes that deposit in tissues, particularly in the kidneys, skin, joints, and blood vessels, activating complement and recruiting inflammatory cells.

Clinical manifestations of SLE are highly variable, and no single feature is present in all patients. Constitutional symptoms (fatigue, fever, weight loss) are common. Mucocutaneous involvement includes the characteristic malar ("butterfly") rash sparing nasolabial folds, discoid rash with scarring, photosensitivity, and oral ulcers. Musculoskeletal involvement typically manifests as non-erosive polyarthritis. Lupus nephritis is a major cause of morbidity and mortality, classified histologically into six classes based on renal biopsy findings, with proliferative (class III and IV) and membranous (class V) nephritis requiring immunosuppressive treatment. Hematologic abnormalities include hemolytic anemia, leukopenia, lymphopenia, and thrombocytopenia. Neuropsychiatric lupus encompasses seizures, psychosis, and other CNS manifestations. Serositis (pleuritis, pericarditis) can cause chest pain and effusions. Cardiovascular complications include accelerated atherosclerosis and Libman-Sacks endocarditis.

Autoantibodies in SLE are diagnostically important and some correlate with specific manifestations. ANA is present in virtually all patients and serves as a sensitive screening test, though it is not specific for SLE. Anti-double-stranded DNA (anti-dsDNA) antibodies are highly specific for SLE, correlate with disease activity, and are associated with lupus nephritis. Anti-Smith (anti-Sm) antibodies, directed against small nuclear ribonucleoproteins, are the most specific for SLE but are present in only about 30% of patients. Anti-Ro (SS-A) and anti-La (SS-B) antibodies are associated with Sjogren's overlap, photosensitivity, and neonatal lupus (including congenital heart block when maternal antibodies cross the placenta). Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta2-glycoprotein I) are associated with thrombosis and pregnancy morbidity, defining antiphospholipid syndrome when present with clinical events.

<image> Panel A: SLE pathogenesis showing impaired apoptotic cell clearance, release of nuclear antigens (DNA, histones, nucleosomes), immune complex formation with anti-dsDNA and other antinuclear antibodies, type I interferon production by plasmacytoid DCs stimulated through TLR7/9, and immune complex deposition in target tissues with complement activation Panel B: Clinical manifestations diagram showing multi-organ involvement: malar rash and discoid lesions (skin), arthritis (joints), serositis (serosal surfaces), nephritis (kidneys), cytopenias (blood), neuropsychiatric manifestations (CNS), with approximate frequencies for each Panel C: Lupus nephritis classification showing Class I (minimal mesangial), Class II (mesangial proliferative), Class III (focal proliferative), Class IV (diffuse proliferative, most severe), Class V (membranous), and Class VI (sclerotic), with representative histology patterns and clinical implications Panel D: Autoantibody associations in SLE showing ANA (sensitive but not specific), anti-dsDNA (specific, correlates with nephritis and activity), anti-Smith (most specific), anti-Ro/La (Sjogren's overlap, photosensitivity, neonatal lupus), and antiphospholipid antibodies (thrombosis, pregnancy loss), with their typical patterns and clinical utility </image>

VII. Rheumatoid Arthritis and Spondyloarthropathies

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease characterized by symmetric polyarthritis affecting primarily small joints of the hands and feet, with progressive joint destruction if untreated. Unlike osteoarthritis, which involves mechanical cartilage degeneration, RA is driven by immune-mediated synovial inflammation that erodes cartilage and bone from the joint margins inward. Early diagnosis and treatment with disease-modifying antirheumatic drugs (DMARDs) can prevent joint damage, making RA an important condition to recognize and treat aggressively.

The pathogenesis of RA involves both genetic and environmental factors converging on the synovium. HLA-DR4 and related alleles sharing a specific amino acid sequence in the peptide-binding groove (the "shared epitope") confer the strongest genetic risk. Environmental factors include smoking, which is associated with anti-citrullinated protein antibodies (ACPA) and increased disease risk and severity. Citrullination, the post-translational modification of arginine to citrulline by peptidylarginine deiminases (PADs), generates neoantigens that are recognized as foreign. Citrullinated proteins may be presented more efficiently by shared epitope HLA-DR molecules, explaining the gene-environment interaction. Within the synovium, CD4+ T cells, B cells, and macrophages accumulate and interact, producing inflammatory cytokines including TNF-alpha, IL-1, and IL-6 that drive synovial inflammation and systemic features. The inflamed synovium forms pannus, a mass of proliferating synoviocytes and inflammatory cells that invades and destroys articular cartilage and subchondral bone.

Sjogren's syndrome is a chronic autoimmune disease targeting exocrine glands, particularly salivary and lacrimal glands, causing dry mouth (xerostomia) and dry eyes (keratoconjunctivitis sicca), collectively termed sicca syndrome. It can occur as primary Sjogren's or secondary to other autoimmune diseases, especially RA and SLE. Histologically, lymphocytic infiltration of affected glands leads to acinar destruction and fibrosis. Anti-Ro (SS-A) and anti-La (SS-B) antibodies are characteristic. Beyond sicca symptoms, patients may experience extraglandular manifestations including fatigue, arthritis, vasculitis, and interstitial lung disease. A significant concern is the markedly increased risk of B cell non-Hodgkin lymphoma (40-fold elevated), particularly mucosa-associated lymphoid tissue (MALT) lymphoma arising from chronically stimulated B cells in salivary glands.

Ankylosing spondylitis (AS) is the prototypical spondyloarthropathy, distinguished from RA by its predilection for the axial skeleton (sacroiliac joints and spine), association with HLA-B27 (present in over 90% of patients), and distinct pathophysiology involving enthesitis (inflammation at tendon and ligament insertions into bone) rather than primarily synovitis. Clinical features include inflammatory back pain (insidious onset, morning stiffness, improvement with exercise) beginning in early adulthood, progressive spinal fusion creating characteristic "bamboo spine" radiographic appearance, and limited spinal mobility. Extra-articular manifestations include acute anterior uveitis (common, often recurrent), cardiac conduction abnormalities and aortic insufficiency, and association with inflammatory bowel disease. The mechanism linking HLA-B27 to disease remains debated, with hypotheses including presentation of arthritogenic peptides, B27 misfolding causing cellular stress, and aberrant B27 heavy chain forms stimulating pathological immune responses.

<image> Panel A: Rheumatoid arthritis pathogenesis showing genetic risk (HLA-DR4 shared epitope), environmental trigger (smoking promoting citrullination), immune response to citrullinated proteins, synovial inflammation with T cell, B cell, and macrophage infiltration, cytokine production (TNF-alpha, IL-1, IL-6), pannus formation, and cartilage and bone erosion from joint margins Panel B: RA joint pathology showing comparison of normal joint versus RA joint with synovial hyperplasia, pannus invading cartilage, marginal bone erosions, and characteristic radiographic changes (juxta-articular osteopenia, joint space narrowing, erosions) Panel C: Sjogren's syndrome showing lymphocytic infiltration of salivary and lacrimal glands, gland destruction leading to sicca symptoms, anti-Ro and anti-La antibodies, and the spectrum from sicca to extraglandular manifestations including lymphoma risk Panel D: Ankylosing spondylitis showing sacroiliitis (bilateral, symmetric), syndesmophyte formation and progressive spinal fusion, HLA-B27 association, enthesitis concept (inflammation at tendon-bone junction), and extra-articular features (uveitis, cardiac involvement, IBD association) </image>

VIII. Vasculitis and Other Systemic Diseases

Systemic vasculitides are inflammatory diseases affecting blood vessels, classified by the predominant vessel size involved (large, medium, or small) and the presence or absence of specific autoantibodies. Vasculitis causes tissue damage through vessel inflammation leading to stenosis (with downstream ischemia), aneurysm formation (with risk of rupture), and transmural inflammation (with hemorrhage and organ damage). The clinical presentation depends on which vascular bed is involved and the extent of vascular compromise.

ANCA-associated vasculitides (AAV) are small vessel vasculitides defined by the presence of anti-neutrophil cytoplasmic antibodies (ANCA), which are directed against proteins in neutrophil granules. Two main ANCA specificities exist: cytoplasmic ANCA (c-ANCA) typically targeting proteinase 3 (PR3), associated with granulomatosis with polyangiitis (GPA, formerly Wegener's); and perinuclear ANCA (p-ANCA) typically targeting myeloperoxidase (MPO), associated with microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss). GPA classically involves the upper respiratory tract (sinusitis, nasal crusting, septal perforation), lower respiratory tract (pulmonary nodules, alveolar hemorrhage), and kidneys (rapidly progressive glomerulonephritis), though it can affect virtually any organ. ANCA activate neutrophils that adhere to vessel walls and release reactive oxygen species and proteases causing endothelial damage.

Systemic sclerosis (scleroderma) is characterized by fibrosis of the skin and internal organs, vasculopathy, and autoimmunity. Two main subtypes exist: limited cutaneous systemic sclerosis, where skin fibrosis is confined to the distal extremities and face, associated with anti-centromere antibodies and risk of pulmonary arterial hypertension; and diffuse cutaneous systemic sclerosis, with more extensive skin involvement, associated with anti-topoisomerase I (anti-Scl-70) antibodies and risk of interstitial lung disease and renal crisis. The CREST acronym (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasias) describes features common in limited disease. The underlying pathophysiology involves vascular injury, immune activation, and fibroblast activation with excessive collagen deposition.

Inflammatory myopathies include dermatomyositis, polymyositis, and inclusion body myositis, characterized by immune-mediated skeletal muscle inflammation and weakness. Dermatomyositis presents with characteristic skin findings (heliotrope rash around eyes, Gottron papules over knuckles, V-sign and shawl sign) along with proximal muscle weakness, and is associated with increased malignancy risk requiring age-appropriate cancer screening. Multiple myositis-specific autoantibodies have been identified, including anti-Mi-2 (associated with classic dermatomyositis, good prognosis), anti-MDA5 (associated with rapidly progressive interstitial lung disease), and anti-Jo-1 (associated with antisynthetase syndrome including ILD, mechanic's hands, and arthritis). Antiphospholipid syndrome (APS) can occur as primary APS or secondary to SLE, defined by the presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta2-glycoprotein I) with clinical events including venous and/or arterial thrombosis and pregnancy morbidity (recurrent miscarriage, preeclampsia, placental insufficiency). Paradoxically, despite being detected by prolongation of in vitro clotting tests, these antibodies are prothrombotic in vivo.

<image> Panel A: ANCA-associated vasculitis showing ANCA binding to neutrophil surface antigens (PR3, MPO), neutrophil activation and adherence to vessel endothelium, degranulation releasing ROS and proteases, vessel wall necrosis and fibrinoid necrosis, with clinical manifestations of GPA (upper and lower respiratory involvement, glomerulonephritis) and histology of pauci-immune crescentic GN Panel B: Systemic sclerosis pathophysiology showing vascular injury (Raynaud's, intimal proliferation), immune activation (autoantibodies, cytokine production), and fibroblast activation with excessive collagen deposition, comparison of limited (CREST, anti-centromere, PAH risk) versus diffuse (anti-Scl-70, ILD risk, renal crisis) subtypes Panel C: Inflammatory myopathies showing clinical features (proximal weakness, elevated CK, characteristic rashes in DM), histology (muscle fiber necrosis, inflammatory infiltrates with different patterns in DM versus PM), myositis-specific antibodies and their clinical associations, and malignancy association with DM Panel D: Antiphospholipid syndrome showing antiphospholipid antibodies (LAC, aCL, anti-beta2-GP1), their prothrombotic mechanisms (endothelial activation, platelet activation, complement activation, interference with anticoagulant pathways), clinical manifestations (venous thrombosis, arterial thrombosis, pregnancy morbidity), and treatment (anticoagulation) </image>

IX. Autoantibody Testing

Autoantibody testing is an essential component of the evaluation of suspected autoimmune disease, but proper interpretation requires understanding test characteristics, clinical context, and the distinction between screening and confirmatory tests. Autoantibodies can serve multiple purposes: diagnosis (supporting clinical suspicion), classification (fulfilling diagnostic criteria), prognosis (predicting disease severity or complications), and monitoring (tracking disease activity). However, autoantibodies must always be interpreted in clinical context, as many can be present in healthy individuals or in conditions other than the classically associated disease.

Antinuclear antibodies (ANA) are the most commonly ordered autoantibody screening test, detected by immunofluorescence on HEp-2 cells (a human epithelial cell line providing diverse nuclear antigens). A positive ANA at low titer (1:40-1:80) occurs in 20-30% of healthy individuals, especially older women, limiting specificity. Higher titers (1:160 and above) are more specific but still not diagnostic of any particular disease. The immunofluorescence pattern provides additional information: homogeneous patterns suggest anti-dsDNA or anti-histone antibodies; speckled patterns suggest anti-Sm, anti-RNP, anti-Ro, or anti-La; nucleolar patterns suggest anti-RNA polymerase or anti-fibrillarin (associated with scleroderma); and centromere patterns are highly specific for limited systemic sclerosis.

Disease-specific autoantibodies provide greater diagnostic utility than ANA alone. Anti-dsDNA and anti-Smith antibodies are highly specific for SLE, with anti-dsDNA levels often fluctuating with disease activity. Anti-CCP (cyclic citrullinated peptide) antibodies are more specific than rheumatoid factor for RA and predict erosive disease. ANCA testing (by immunofluorescence and specific ELISAs for PR3 and MPO) is essential for diagnosing ANCA-associated vasculitis. Anti-thyroid antibodies (anti-TPO, anti-thyroglobulin) support autoimmune thyroid disease diagnosis. Anti-mitochondrial antibodies are highly specific for primary biliary cholangitis. Each autoantibody has its own sensitivity and specificity for the associated condition, and clinical correlation is always essential.

Interpretation caveats are important to avoid misdiagnosis and unnecessary treatment. Low-titer autoantibodies in healthy individuals are common, and treatment should never be based on autoantibodies alone without compatible clinical findings. Autoantibodies can precede clinical disease by years (as in T1DM or SLE), identifying individuals at risk but not necessarily requiring treatment. Some autoantibodies can be induced by drugs (anti-histone antibodies in drug-induced lupus) or infections. Autoantibody panels can lead to false positive results due to multiple comparisons, and reflexive ordering of extensive panels without clinical indication generates confusion and unnecessary follow-up. The principle of ordering tests directed by clinical suspicion, rather than screening broadly, optimizes diagnostic utility.

<image> Panel A: ANA immunofluorescence patterns on HEp-2 cells showing homogeneous (anti-dsDNA, anti-histone), speckled (anti-Sm, anti-RNP, anti-Ro, anti-La), nucleolar (anti-RNA polymerase, scleroderma), and centromere (limited systemic sclerosis) patterns, with representative microscopic images and clinical associations Panel B: Disease-specific autoantibody characteristics showing sensitivity and specificity for key antibodies: anti-dsDNA (SLE specific, correlates with activity), anti-Smith (most SLE specific, ~30% sensitivity), anti-CCP (RA specific, predicts erosions), ANCA PR3 (GPA), ANCA MPO (MPA, EGPA), with receiver operating characteristic concepts Panel C: Interpretation algorithm showing clinical suspicion guiding targeted autoantibody testing, interpretation in context of pre-test probability, significance of titer and pattern, need for confirmatory testing, and avoidance of treating autoantibodies alone Panel D: Common pitfalls in autoantibody testing showing low-titer ANA in healthy elderly, drug-induced autoantibodies (hydralazine, procainamide causing anti-histone), infection-associated transient autoantibodies, and the problem of broad panel ordering generating false positives and diagnostic confusion </image>

X. Treatment of Autoimmune Diseases

The treatment of autoimmune diseases has evolved dramatically over recent decades, from reliance on corticosteroids and non-specific immunosuppressants to targeted biologic therapies and emerging approaches toward antigen-specific tolerance induction. Treatment goals include controlling disease activity, preventing organ damage, minimizing treatment toxicity, and optimizing quality of life. The approach varies by disease, severity, and organ involvement, with the general principle of using the least immunosuppression necessary to achieve disease control.

Corticosteroids remain the most rapidly effective anti-inflammatory agents and are essential for controlling acute flares of most autoimmune diseases. They act through multiple mechanisms including suppression of inflammatory gene transcription, induction of anti-inflammatory genes, and effects on leukocyte trafficking and function. However, the extensive side effect profile (osteoporosis, diabetes, hypertension, infection risk, weight gain, cataracts, avascular necrosis) limits long-term use, and steroid-sparing strategies are a major goal of autoimmune disease management. Pulse methylprednisolone is used for severe manifestations such as rapidly progressive glomerulonephritis or severe neuropsychiatric lupus, while lower maintenance doses are used during taper and for chronic suppression when necessary.

Conventional disease-modifying antirheumatic drugs (DMARDs) form the backbone of treatment for many autoimmune diseases. Methotrexate, the anchor drug for rheumatoid arthritis, acts through multiple mechanisms including adenosine release and anti-inflammatory effects beyond its antiproliferative action. Azathioprine and mycophenolate mofetil inhibit purine synthesis, affecting rapidly dividing lymphocytes. Cyclophosphamide, an alkylating agent, is reserved for severe manifestations such as lupus nephritis, ANCA-associated vasculitis, and severe interstitial lung disease due to its significant toxicity including gonadal toxicity and malignancy risk. Hydroxychloroquine is used in SLE for its immunomodulatory effects and protective effects against flares, thrombosis, and damage accrual.

Biologic therapies targeting specific cytokines, cell surface molecules, or cell populations have transformed treatment of autoimmune diseases over the past two decades. TNF inhibitors (infliximab, adalimumab, etanercept) revolutionized RA treatment and are effective in spondyloarthropathies, psoriasis, and inflammatory bowel disease. Rituximab (anti-CD20) depletes B cells and is effective in RA, ANCA-associated vasculitis, and increasingly in SLE. Abatacept (CTLA-4-Ig) blocks costimulation and is approved for RA. Tocilizumab (anti-IL-6R) is effective in RA and giant cell arteritis. Belimumab (anti-BAFF) was the first biologic approved specifically for SLE. IL-17 and IL-23 inhibitors are effective in psoriasis and spondyloarthropathies. JAK inhibitors (tofacitinib, baricitinib, upadacitinib) are oral small molecules that block cytokine signaling and are effective in RA and other conditions. Emerging approaches include CAR-T cells targeting autoreactive B cells and antigen-specific tolerance induction strategies.

<image> Panel A: Corticosteroid mechanisms and toxicities showing genomic effects (GR binding DNA, suppressing inflammatory genes, inducing anti-inflammatory genes), non-genomic effects, and comprehensive side effect diagram organized by organ system (metabolic, skeletal, infectious, cardiovascular, dermatologic, ophthalmologic) Panel B: Conventional DMARDs showing mechanisms of action for methotrexate (DHFR inhibition, adenosine release), azathioprine (purine synthesis inhibition via 6-MP), mycophenolate (IMPDH inhibition), and cyclophosphamide (DNA alkylation), with key toxicities and monitoring for each Panel C: Biologic therapies in autoimmunity showing TNF inhibitors (mechanism, diseases), B cell depletion with rituximab (mechanism, diseases), costimulation blockade with abatacept, and cytokine-targeted therapies (anti-IL-6R, anti-IL-17, anti-IL-23, anti-BAFF), organized by target Panel D: Treatment algorithm showing approach to autoimmune disease: disease activity assessment, induction therapy for active disease (corticosteroids plus DMARD or biologic depending on severity), maintenance therapy with steroid-sparing agents, monitoring for response and toxicity, and adjustment based on outcomes </image>

Summary

• Central tolerance (thymic negative selection, AIRE) and peripheral tolerance (anergy, deletion, Tregs) prevent autoimmunity; failure requires multiple hits
• Genetic factors (HLA associations, immune regulatory genes) combine with environmental triggers (infections, molecular mimicry, bystander activation)
• Type II hypersensitivity involves autoantibodies causing cytotoxicity or receptor dysfunction; Type III involves immune complex deposition; Type IV involves T cell-mediated damage
• T1DM involves CD8+ CTL destruction of beta cells with characteristic autoantibodies (anti-GAD, anti-IA2, anti-insulin) but T cell-mediated pathogenesis
• Autoimmune thyroid diseases include Hashimoto's (destructive, hypothyroidism) and Graves' (stimulating TSI antibodies, hyperthyroidism)
• MS involves demyelination by Th1/Th17 cells and microglia/macrophages; MG involves anti-AChR antibodies causing neuromuscular junction dysfunction
• SLE features anti-nuclear autoantibodies, immune complex deposition, type I interferon signature, and multi-organ involvement; anti-dsDNA correlates with nephritis
• RA involves synovial inflammation with pannus destroying cartilage and bone; HLA-DR4 shared epitope and anti-CCP antibodies are characteristic
• ANCA-associated vasculitis involves c-ANCA/PR3 (GPA) or p-ANCA/MPO (MPA); systemic sclerosis involves fibrosis, vasculopathy, and specific autoantibodies
• Treatment includes corticosteroids for acute flares, conventional DMARDs for maintenance, and targeted biologics (anti-TNF, rituximab, abatacept)

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown